Contineum Therapeutics, Inc. Sample Contracts
CONTINEUM THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • May 14th, 2025 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • New York
Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Contineum Therapeutics, Inc. (a Delaware corporation) [•] Shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • April 1st, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
ContractWarrant Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LEASE AGREEMENTLease Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 25 day of October, 2023 (the “Effective Date”), between ARE-3535/3565 GENERAL ATOMICS COURT, LLC, a Delaware limited liability company (“Landlord”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
AMENDED AND RESTATED]1 INDEMNITY AGREEMENTIndemnity Agreement • April 1st, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • California
THIS [AMENDED AND RESTATED] INDEMNITY AGREEMENT (this “Agreement”) dated as of ________________, is made by and between Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), and _____________ (“Indemnitee”).
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of July 9, 2021 by and between Pipeline Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated and effective as of September 1, 2020 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
CONTINEUM THERAPEUTICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENTSales Agreement • March 5th, 2026 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • New York
Reference is made to the Sales Agreement, dated May 14, 2025 (the “Sales Agreement”), by and between Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC ( the “Agent”), pursuant to which the Company agreed, in its sole discretion, to issue and sell, from time to time, through the Agent, as agent and/or principal, up to an aggregate of $75,000,000 of shares of common stock, par value $0.001 per share, of the Company. All capitalized terms used in this Amendment No. 1 to the Sales Agreement (this “Amendment”) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Sales Agreement. The Company and the Agent hereby agree to amend the Sales Agreement as set forth in this Amendment as follows:
LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICA NV AND PIPELINE THERAPEUTICS, INC. Dated February 3, 2023License Agreement • December 13th, 2023 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into as of February 3, 2023 (the “Execution Date”) by and between Pipeline Therapeutics, Inc., a Delaware corporation (“Licensor”), on the one hand, and Janssen Pharmaceutica NV, a Belgium company (“Janssen”), on the other hand. Licensor and Janssen are referred to in this Agreement each individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICA NV AND PIPELINE THERAPEUTICS, INC. Dated February 3, 2023License Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into as of February 3, 2023 (the “Execution Date”) by and between Pipeline Therapeutics, Inc., a Delaware corporation (“Licensor”), on the one hand, and Janssen Pharmaceutica NV, a Belgium company (“Janssen”), on the other hand. Licensor and Janssen are referred to in this Agreement each individually as a “Party” and collectively as the “Parties.”
Contineum Therapeutics, Inc. (a Delaware corporation) 7,346,938 Shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • December 15th, 2025 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,346,938 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,102,040 additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • California
This FIRST AMENDMENT to Loan and Security Agreement (this “Agreement”) is entered into as of March 15, 2021, by and between SILICON VALLEY BANK, a California corporation (“Bank”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Borrower”).
AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISESTermination of Lease Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of October 25 , 2023, by and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Tenant”), with reference to the following:
THIRD AMENDMENT TO LEASELease Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of June 15, 2021, by and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
MUTUAL ARBITRATION AGREEMENTMutual Arbitration Agreement • May 31st, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
To the fullest extent permitted by applicable law, you and Contineum Therapeutics, Inc., including its current or former parent, affiliate, subsidiary, successor, or predecessor, (the “Company”) (individually, “Party,” or collectively, “Parties”) enter into this Mutual Arbitration Agreement (the “Agreement”) and agree to arbitrate any and all disputes, demands, claims, or controversies (collectively, “Claim” or “Claims”) relating to, arising from or regarding your employment or relationship with the Company, including Claims by the Company, Claims against the Company, and Claims against the Company’s respective officers, directors, members, agents, or employees. This Agreement will preclude the Parties from bringing any class, collective, coordinated, consolidated, and/or representative action against each other.
FIRST AMENDMENT TO LEASELease Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Lease (this “First Amendment”) is made as of February 16, 2018, by and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
PIPELINE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 9th day of February, 2021, by and among PIPELINE THERAPEUTICS, INC. (f/k/a Sirocco Therapeutics, Inc.), a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
May 31, 2024Advisor Agreement • May 14th, 2025 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • California
This Advisor Agreement (“Agreement”) is made by and between Contineum Therapeutics, Inc. (“Company”) and Diego Miralles (“Advisor”), effective as of June 1, 2024 (the “Effective Date”). Company desires to benefit from Advisor’s expertise and experience by retaining Advisor, and Advisor wishes to perform consulting services for Company, as provided for below. Accordingly, Company and Advisor agree as follows:
SECOND AMENDMENT TO LEASELease Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of April 2, 2018, by and between ARE-SO REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and PIPELINE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).